GLP-1 medications such as Ozempic and Wegovy intentionally slow digestion, but in rare cases this effect can progress to gastroparesis. Learn how to recognize warning signs, understand risk factors, and know when medical evaluation is necessary.
Rapid GLP-1 weight loss is transforming more than obesity treatment. As facial fat loss and skin laxity rise, regenerative aesthetics and collagen-stimulating biotechnology are becoming a booming parallel economy.
GLP-1 medications are transforming obesity treatment, but nausea and vomiting remain major barriers to long-term adherence. Here’s what clinicians now understand about why these side effects occur — and why slower titration may matter more than the drug itself.
Retatrutide may become the next major breakthrough in obesity medicine. Here’s how the investigational triple-agonist compares with Wegovy, Mounjaro, and other GLP-1 medications for weight loss and metabolic health.
A major clinical trial found that tirzepatide produced greater average weight loss than semaglutide over 72 weeks. Here’s what researchers believe explains the difference between these two leading obesity medications.
New clinical trial data show that Zepbound users lost significantly more weight than Wegovy users over 72 weeks. Here’s how tirzepatide and semaglutide compare in effectiveness, side effects, cardiovascular benefits, and obesity treatment outcomes.
Celebrities using GLP-1 weight-loss drugs like Ozempic and Wegovy are bringing attention to “Ozempic Face.” These facial changes are linked to rapid weight loss, not the medication itself, and can often improve over time.